49 completed, 8 terminated, 8 unknown, 3 recruiting. 26 Phase 2, 19 Phase 3, 12 Phase 4, 6 Not applicable, 2 Phase 1.
Follow Caspofungin: new trials by email Literature Review of Caspofungin trials Research Report on Caspofungin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Shortening Treatment Duration in Uncomplicated Candidemia: the CanTEN Trial Caspofungin only within the study, Caspofungin for 3 days within the study, Placebo only within the study - Candidemia, Invasive Candidiasis | Phase 4 | Not yet recruiting | Oliver Cornely, MD | 420 | 2026-09-01 | 2026-09-01 |
| CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia Caspofungin Acetate 50 MG, Physiologic saline - Pneumocystis Pneumonia, Pneumocystis Jirovecii Infection | Phase 1 / Phase 2 | Recruiting | University Hospital, Tours | 100 | 2025-12-02 | 2026-10-09 |
| A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. Fosmanogepix, Caspofungin, Fluconazole - Candidemia, Candidiasis, Invasive | Phase 3 | Recruiting | Basilea Pharmaceutica | 450 | 2024-12-11 | 2026-10-19 |
| A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis HRS9432, Caspofungin Acetate for Injection - Patients With Candidemia and/or Invasive Candidiasis | Phase 2 | Completed | Fujian Shengdi Pharmaceutical Co., Ltd. | 61 | 2024-04-27 | 2026-09-10 |
| To Evaluate the Efficacy and Safety of Micafungin in Preventing Invasive Mycosis After Liver Transplantation Micafungin Sodium 50 MG Injection, Caspofungin Acetate - Liver Transplantation | Phase 4 | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 200 | 2022-10-01 | 2022-08-16 |
| PK/PD of Caspofungin in Children Severe Infection Caspofungin - Pharmacokinetics, Infection, Fungal | Recruiting | Children's Hospital of Fudan University | 60 | 2022-10-01 | 2026-02-17 | |
| Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics Combined with voriconazole, Combined with caspofungin, Tacrolimus-alone treatment - Kidney Transplant Patients | Completed | LI YAN | 507 | 2022-09-01 | 2023-09-28 | |
| A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole SCY-078, Fluconazole, Echinocandin - Candidiasis, Invasive, Candidemia | Phase 3 | Terminated | Scynexis, Inc. | 68 | 2022-08-03 | 2026-08-10 |
| Trimethoprim/Sulfamethoxazole Combined With Caspofungin as First-line Therapy in PCP caspofungin, TMP/SMZ(trimethoprim/sulfisoxazole), Methylprednisolone - Pneumocystis Pneumonia | Phase 4 | Unknown | Bin Du | 122 | 2019-08-14 | 2019-09-12 |
| Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis Rezafungin for Injection, Caspofungin, Fluconazole - Candidemia, Mycoses | Phase 3 | Completed | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 199 | 2018-10-07 | 2023-01-06 |
| Empiric Therapy of Patients With Persistent Fever and Agranulocytosis Using Caspofungin Caspofungin - Fungal Infection | Phase 2 | Completed | Cttq | 32 | 2018-09-17 | 2021-07-07 |
| Pharmacokinetics of Caspofungin Caspofungin - Septic Shock, Fungal Infection | Completed | Medical University of Lublin | 33 | 2018-02-05 | 2023-11-24 | |
| Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients F901318, Caspofungin - Pulmonary Aspergillosis - Invasive, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | F2G Ltd | 2017-04-20 | 2018-02-15 | |
| Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis (EPI Study) Echinocandins - Septic Shock, Peritonitis | Phase 4 | Completed | Centre Hospitalier Universitaire de Nīmes | 24 | 2017-01-28 | 2025-12-10 |
| A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy Itraconazole, Caspofungin - Hematologic Neoplasms | Phase 4 | Terminated | Xian-Janssen Pharmaceutical Ltd. | 61 | 2016-11-30 | 2019-05-06 |
| CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension CD101, Caspofungin, Fluconazole - Candidemia, Mycoses | Phase 2 | Completed | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 207 | 2016-07-26 | 2020-12-08 |
| Pharmacokinetics/Pharmacodynamics (PK/PD) of Caspofungin in Intensive Care Unit (ICU) Patients. An Open Observational Study for Antifungal Treatment's Optimization Caspofungin - Critical Illness, Infection | Completed | Careggi Hospital | 20 | 2016-01-01 | 2019-01-17 | |
| Effects and Safety of Caspofungin and Corticosteroids in Pneumocystis Pneumonia in Non-HIV Patients caspofungin, corticosteroids, Sulfanilamides - Pneumocystis Pneumonia | Not applicable | Unknown | Beijing Chao Yang Hospital | 60 | 2015-11-01 | 2020-03-13 |
| Evaluation of the Pharmacokinetics of Caspofungin in ICU Patients Caspofungin - Shock | Not applicable | Completed | Centre Hospitalier Universitaire de Saint Etienne | 50 | 2015-03-16 | 2019-06-14 |
| Pharmacokinetics and Pharmacodynamics of Caspofungin (Cancidas ®) and Drug Tolerance of Fungi to Patients With an Invasive Fungal Infection in the Intensive Care Unit Caspofungin - Invasive Fungal Infection | Not applicable | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 40 | 2014-07-01 | 2015-07-28 |
Showing 20 of 70. Sign in to see all of them.
Mycoses (26) · Candidiasis (12) · Candidiasis, Invasive (12) · Invasive Fungal Infections (10) · Candidemia (8) · Aspergillosis (7) · Infections (6) · Leukemia (5) · Leukemia, Myeloid, Acute (5) · Neutropenia (4) · Burkitt Lymphoma (3) · Critical Illness (3) · Fever (3) · Fungemia (3) · Invasive Pulmonary Aspergillosis (3)
Merck Sharp & Dohme LLC (16) · Astellas Pharma Inc (4) · Children's Oncology Group (2) · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · National Cancer Institute (NCI) (2) · Assistance Publique - Hôpitaux de Paris (1) · Astellas Pharma Europe B.V. (1) · Azienda Ospedaliera di Padova (1) · Basilea Pharmaceutica (1) · Beijing Chao Yang Hospital (1) · Bin Du (1) · Careggi Hospital (1) · Centre Hospitalier Universitaire de Nīmes (1) · Centre Hospitalier Universitaire de Saint Etienne (1)
United States (20) · China (13) · France (13) · Germany (12) · Belgium (11) · Italy (9) · Spain (9) · Canada (6) · Brazil (5) · Argentina (4) · Australia (4) · Bulgaria (4) · Greece (4) · Israel (4) · Netherlands (4)
Alexandra Hill, MD (1) · Andreas Groll, M.D. (1) · Chiara Cattaneo (1) · Christophe Vinsonneau, MD (1) · Christopher C Dvorak (1) · Claire Roger, MD (1) · Claudio Viscoli, MD (1) · Daniele Neri, MD (1) · Danny Benjamin, MD (1) · David Angulo, MD (1) · Feng Ye, MD (1)
PMID 38008099, PMID 38502709, PMID 39468640, PMID 39529079, PMID 41940006, PMID 15459300, PMID 16304338, PMID 16505648, PMID 18046534, PMID 19172247, PMID 19841031, PMID 20431381, PMID 20946413, PMID 21147825, PMID 21729932, PMID 21911573, PMID 22548840, PMID 22585216, PMID 23052987, PMID 23335740, PMID 23459494, PMID 23940606, PMID 23959319, PMID 24550378, PMID 25139840, PMID 25520332, PMID 25701307, PMID 25902926, PMID 26935726, PMID 27855112, PMID 29860319, PMID 30289478, PMID 30776290, PMID 31548210, PMID 31586424, PMID 31633150, PMID 31688884, PMID 32194238, PMID 32202224, PMID 32601169, PMID 32955088, PMID 33136159, PMID 33438477, PMID 33846133, PMID 35906831, PMID 36442484, PMID 38985561, PMID 39259571, PMID 41151592, PMID 41194465
2008 (2), U10CA095861 (2), UG1CA189955 (2), 2009 (1), 2014 (1), 2015 (1), 2016 (1), 2023 (1), 5UL1RR024982-02 (1)